Niagen Bioscience Inc (NAGE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NAGE Revenue Growth
NAGE Revenue Analysis (2014–2025)
As of May 8, 2026, Niagen Bioscience Inc (NAGE) generated trailing twelve-month (TTM) revenue of $129.4 million, reflecting strong growth of +16.2% year-over-year. The most recent quarter (Q4 2025) recorded $33.8 million in revenue, down 0.4% sequentially.
Looking at the longer-term picture, NAGE's 5-year compound annual growth rate (CAGR) stands at +16.9%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $129.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including NRXP, HALO (+37.6% YoY), and NBIX (+28.6% YoY), NAGE has underperformed the peer group in terms of revenue growth. Compare NAGE vs NRXP →
NAGE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NAGECurrent | $129M | +16.2% | +16.9% | 11.0% | |
 NRXP | $1M | - | - | -1324.4% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 NBIX | $2.9B | +28.6% | +22.3% | 21.6% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
NAGE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $129.4M | +29.9% | $83.2M | 64.3% | $14.3M | 11.0% |
| 2024 | $99.6M | +19.2% | $61.6M | 61.8% | $7.7M | 7.8% |
| 2023 | $83.6M | +16.0% | $50.8M | 60.8% | $-5,599,000 | -6.7% |
| 2022 | $72.0M | +6.8% | $42.8M | 59.4% | $-18,628,000 | -25.9% |
| 2021 | $67.4M | +13.8% | $41.5M | 61.5% | $-27,073,000 | -40.1% |
| 2020 | $59.3M | +28.0% | $35.3M | 59.5% | $-19,854,000 | -33.5% |
| 2019 | $46.3M | +46.7% | $25.8M | 55.7% | $-31,300,000 | -67.6% |
| 2018 | $31.6M | +48.8% | $16.1M | 50.9% | $-33,172,000 | -105.1% |
| 2017 | $21.2M | -2.1% | $10.5M | 49.4% | $-16,377,000 | -77.2% |
| 2016 | $21.7M | +21.1% | $10.4M | 48.0% | $-2,905,210 | -13.4% |
See NAGE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAGE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAGE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNAGE — Frequently Asked Questions
Quick answers to the most common questions about buying NAGE stock.
Is NAGE's revenue growth accelerating or slowing?
NAGE revenue is accelerating at +16.2% year-over-year, exceeding the 5-year CAGR of +16.9%. TTM revenue reached $129M. Growth momentum has increased versus prior periods.
What is NAGE's long-term revenue growth rate?
Niagen Bioscience Inc's 5-year revenue CAGR of +16.9% reflects the sustained expansion pattern. Current YoY growth of +16.2% is above this long-term average.
How is NAGE's revenue distributed by segment?
NAGE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.